Randomized, controlled trial of a 10-day course of amifloxacin versus trimethoprim-sulfamethoxazole in the treatment of acute, uncomplicated urinary tract infection. Amifloxacin Multi-Center Trial Group.

Abstract

We conducted a randomized controlled trial of orally administered amifloxacin versus trimethoprimsulfamethoxazole (TMP-SMX) as treatments of acute uncomplicated urinary tract infection in women. Amifloxacin at a dosage of 200 mg twice a day appeared as safe and effective as TMP-SMX, but amifloxacin at 400 mg twice a day tended to cause adverse events more frequently than did TMP-SMX.

• Authors: E J Boyko, A Iravani, M H Silverman, D J Schelling, R A Wright
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 34 Issue 4 Pg. 665-7 (Apr 1990) ISSN: 0066-4804 [Print] United States
• PMID: 2188590 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Infective Agents
• Fluoroquinolones
• Ciprofloxacin
• amifloxacin
• Trimethoprim, Sulfamethoxazole Drug Combination

Topics

• Administration, Oral
• Adult
• Anti-Infective Agents (administration & dosage, adverse effects, therapeutic use)
• Ciprofloxacin (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Dose-Response Relationship, Drug
• Female
• Fluoroquinolones
• Gram-Negative Bacteria (drug effects)
• Gram-Positive Bacteria (drug effects)
• Humans
• Randomized Controlled Trials as Topic
• Trimethoprim, Sulfamethoxazole Drug Combination (administration & dosage, adverse effects, therapeutic use)
• Urinary Tract Infections (drug therapy)